- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05921994
Étude observationnelle, prospective et multicentrique à long terme pour recueillir dans une population réelle des données sur le schéma de traitement du secukinumAb chez les patients adultes atteints d'hidrosadénite suppurée modérée à sévère. (ANIMA)
Étude observationnelle, prospective et multicentrique à long terme pour collecter dans une population réelle des données sur le schéma de traitement du sécukinumAb chez les patients adultes atteints d'hidrosadénite suppurée (HS) modérée à sévère (ANIMA)
The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and decision influencing factors for flexible dosing in a real-world population over 2 years.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
The study will collect data from patients during routine secukinumab treatment and will be representative of the real-world patient population eligible for secukinumab treatment in Germany.
In order to attain widespread representation of health care practices related to the use of secukinumab in the approved indication of moderate to severe HS, a broad spectrum of dermatology practices and clinics who are treating patients with HS across Germany will be included.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Aachen, Allemagne, 52064
- Novartis Investigative Site
-
Ahaus, Allemagne, 48683
- Novartis Investigative Site
-
Annaberg-Buchholz, Allemagne, 09456
- Novartis Investigative Site
-
Bad Steben, Allemagne, 95138
- Novartis Investigative Site
-
Baden-Baden, Allemagne, 76530
- Novartis Investigative Site
-
Berlin, Allemagne, 12159
- Novartis Investigative Site
-
Berlin, Allemagne, 13595
- Novartis Investigative Site
-
Bielefeld, Allemagne, 33647
- Novartis Investigative Site
-
Bochum, Allemagne, 44791
- Novartis Investigative Site
-
Bonn, Allemagne, 53105
- Novartis Investigative Site
-
Brandenburg, Allemagne, 14776
- Novartis Investigative Site
-
Bremen, Allemagne, 28359
- Novartis Investigative Site
-
Buxtehude, Allemagne, 21614
- Novartis Investigative Site
-
Bückeburg, Allemagne, 31675
- Novartis Investigative Site
-
Chemnitz, Allemagne, 09117
- Novartis Investigative Site
-
Chemnitz, Allemagne, 09113
- Novartis Investigative Site
-
Cologne, Allemagne, 51065
- Novartis Investigative Site
-
Delitzsch, Allemagne, 04509
- Novartis Investigative Site
-
Dessau, Allemagne, 06847
- Novartis Investigative Site
-
Dorsten, Allemagne, 46282
- Novartis Investigative Site
-
Dortmund, Allemagne, 44137
- Novartis Investigative Site
-
Dresden, Allemagne, 01309
- Novartis Investigative Site
-
Düren, Allemagne, 52349
- Novartis Investigative Site
-
Emsdetten, Allemagne, 48282
- Novartis Investigative Site
-
Erlangen, Allemagne, 91054
- Novartis Investigative Site
-
Falkenberg, Allemagne, 04895
- Novartis Investigative Site
-
Falkensee, Allemagne, 14612
- Novartis Investigative Site
-
Freising, Allemagne, 85354
- Novartis Investigative Site
-
Geilenkirchen, Allemagne, 52511
- Novartis Investigative Site
-
Gera, Allemagne, 07548
- Novartis Investigative Site
-
Gernsbach, Allemagne, 76593
- Novartis Investigative Site
-
Gladbeck, Allemagne, 45964
- Novartis Investigative Site
-
Großenhain, Allemagne, 01558
- Novartis Investigative Site
-
Hamburg, Allemagne, 20246
- Novartis Investigative Site
-
Hamburg, Allemagne, 22143
- Novartis Investigative Site
-
Hanover, Allemagne, 30159
- Novartis Investigative Site
-
Haslach im Kinzigtal, Allemagne, 77716
- Novartis Investigative Site
-
Hofgeismar, Allemagne, 34369
- Novartis Investigative Site
-
Jena, Allemagne, 07743
- Novartis Investigative Site
-
Jülich, Allemagne, 52428
- Novartis Investigative Site
-
Karlsruhe, Allemagne, 76133
- Novartis Investigative Site
-
Kempen, Allemagne, 47906
- Novartis Investigative Site
-
Lübeck, Allemagne, 23538
- Novartis Investigative Site
-
Magdeburg, Allemagne, 39120
- Novartis Investigative Site
-
Magdeburg, Allemagne, 39104
- Novartis Investigative Site
-
Mainz, Allemagne, 55116
- Novartis Investigative Site
-
Marburg, Allemagne, 35043
- Novartis Investigative Site
-
Minden, Allemagne, 32429
- Novartis Investigative Site
-
Mönchengladbach, Allemagne, 41063
- Novartis Investigative Site
-
Neu Wulmstorf, Allemagne, 21629
- Novartis Investigative Site
-
Nuremberg, Allemagne, 90419
- Novartis Investigative Site
-
Oberasbach, Allemagne, 90522
- Novartis Investigative Site
-
Oelde, Allemagne, 59302
- Novartis Investigative Site
-
Peitz, Allemagne, 03185
- Novartis Investigative Site
-
Potsdam, Allemagne, 14469
- Novartis Investigative Site
-
Remscheid, Allemagne, 42897
- Novartis Investigative Site
-
Selters, Allemagne, 56242
- Novartis Investigative Site
-
Simmern, Allemagne, 55469
- Novartis Investigative Site
-
Soest, Allemagne, 59494
- Novartis Investigative Site
-
Stolberg, Allemagne, 52222
- Novartis Investigative Site
-
Unna, Allemagne, 59423
- Novartis Investigative Site
-
Wittlich, Allemagne, 54316
- Novartis Investigative Site
-
Wuppertal, Allemagne, 42103
- Novartis Investigative Site
-
-
Baden-Wurttemberg
-
Freiburg im Breisgau, Baden-Wurttemberg, Allemagne, 79068
- Novartis Investigative Site
-
Rheinstetten, Baden-Wurttemberg, Allemagne, 76287
- Novartis Investigative Site
-
-
Bavaria
-
Haßfurt, Bavaria, Allemagne, 97437
- Novartis Investigative Site
-
Kulmbach, Bavaria, Allemagne, 95326
- Novartis Investigative Site
-
Lauf an der Pegnitz, Bavaria, Allemagne, 91207
- Novartis Investigative Site
-
Nuremberg, Bavaria, Allemagne, 90402
- Novartis Investigative Site
-
-
Brandenburg
-
Panketal, Brandenburg, Allemagne, 16341
- Novartis Investigative Site
-
-
Free and Hanseatic City of Hamburg
-
Hamburg, Free and Hanseatic City of Hamburg, Allemagne, 22549
- Novartis Investigative Site
-
-
Lower Saxony
-
Lingen, Lower Saxony, Allemagne, 49809
- Novartis Investigative Site
-
-
Mecklenburg-Vorpommern
-
Bergen auf Rügen, Mecklenburg-Vorpommern, Allemagne, 18528
- Novartis Investigative Site
-
Kröpelin, Mecklenburg-Vorpommern, Allemagne, 18236
- Novartis Investigative Site
-
-
North Rhine-Westphalia
-
Krefeld, North Rhine-Westphalia, Allemagne, 47798
- Novartis Investigative Site
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, Allemagne, 55128
- Novartis Investigative Site
-
-
Saxony
-
Dresden, Saxony, Allemagne, 01307
- Novartis Investigative Site
-
Leipzig, Saxony, Allemagne, 04207
- Novartis Investigative Site
-
Leipzig, Saxony, Allemagne, 04289
- Novartis Investigative Site
-
-
Saxony-Anhalt
-
Wittenberg, Saxony-Anhalt, Allemagne, 06886
- Novartis Investigative Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
patients, being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication.
La description
Inclusion Criteria:
Patients eligible for inclusion in this study have to fulfill all of the following criteria at enrollment:
- Patients who provide written informed consent to participate in the study
- Male and female patients with ≥18 years of age
- Diagnosis of clinically unequivocal moderate to severe HS
- Patients for whom a therapy with secukinumab is medically indicated
- Documented decision for treatment with marketed secukinumab regardless of this noninterventional study
- Treatment with secukinumab according to the latest version of SmPC
- Initial treatment with marketed secukinumab planned for up to 1 week before the baseline visit
Exclusion Criteria:
Patients fulfilling any of the following criteria at enrollment are not eligible for inclusion in this study. No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients:
- Patients who have any contraindications, such as a history of or active inflammatory bowel disease (Crohn´s disease, ulcerative colitis), and are not eligible for treatment with secukinumab according to the SmPC
- Any medical or psychological condition in the treating physician's opinion which may prevent the patient from the study participation
- Simultaneous participation in any investigational trial or simultaneous participation in another Novartis-sponsored non-interventional study with secukinumab
- Previous exposure to IL-17 inhibitors
- For biologic-naïve patients, previous exposure to another biologic drug, such as anti-TNF-α inhibitors
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
secukinumab
Patients being treated for HS with secukinumab according to the summary of product characteristics (SmPC), after the approval of secukinumab has been granted in this indication. |
Prospective observational study. There is no treatment allocation. Patients administered secukinumab by prescription and administered according to the SmPC. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Proportion of patients receiving up-titration
Délai: Up to 24 months
|
Proportion of patients receiving up-titration (q4w-to-q2w) |
Up to 24 months
|
|
Proportion of patients receiving down-titration
Délai: Up to 24 months
|
Proportion of patients receiving down-titration (q2w-to-q4w) |
Up to 24 months
|
|
Time to up-titration and down-titration
Délai: Up to 2 years
|
Time to up-titration and down-titration |
Up to 2 years
|
|
Duration of q4w treatment with secukinumab after dose reduction
Délai: Up to 2 years
|
Duration of q4w treatment with secukinumab after dose reduction |
Up to 2 years
|
|
Proportion of patients who receive more than one up-and/or down titration
Délai: Up to 24 months
|
Proportion of patients who receive more than one up-and/or down titration |
Up to 24 months
|
|
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab
Délai: Up to 2 years
|
Proportion of patients receiving HS-specific concomitant treatments in combination with secukinumab |
Up to 2 years
|
|
Number and type of surgical interventions
Délai: Up to 2 years
|
Number and type of surgical interventions
|
Up to 2 years
|
|
Proportion of patients achieving 55% reduction in IHS4 (IHS4-55)
Délai: Up to 24 months
|
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS |
Up to 24 months
|
|
mean change of International Hidradenitis Suppurativa Severity Score System (IHS4)
Délai: Up to 24 months
|
The IHS4 is an exclusively physician-based, clinical scoring system for dynamic assessment of HS severity. HS severity is calculated based on the number of lesions multiplied by their respective score: the IHS4 score (points) = (number of nodules multiplied by 1) + (number of abscesses multiplied by 2) + [number of draining tunnels (fistulae/sinuses) multiplied by 4]. A score of 3 or less signifies mild HS, a score of 4-10 signifies moderate HS and a score of 11 or higher signifies severe HS |
Up to 24 months
|
|
Proportion of patients achieving a 5-point reduction of their Dermatology Life Quality Index (DLQI) questionnaire
Délai: Up to 24 months
|
The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. The measure is self-administered and includes domains of daily activities, leisure, personal relationships, symptoms and feelings, treatment, and work/school. Each item has four response categories ranging from 0 (not at all) to 3 (very much). "Not relevant" is also a valid response and is scored as 0. The DLQI total score is a sum of the 10 questions. Scores range from 0 to 30, with higher scores indicating greater HRQoL impairment. |
Up to 24 months
|
|
Mean reduction of Abscesses and inflammatory nodules (AN) count
Délai: Up to 24 months
|
Mean reduction of Abscesses and inflammatory nodules (AN) count |
Up to 24 months
|
|
Proportion of patients achieving a 30% reduction of pain Numerical Rating scale 30 (NRS30)
Délai: Up to 24 months
|
The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of their pain ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). To assess this, the patient should concentrate on the pain that his/her skin lesions generate. The Patient's Global Assessment of Skin Pain - NRS will be completed by the subject electronically via a web-based application or in paper form. |
Up to 24 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Directeur d'études: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CAIN457MDE01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .